These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38717356)

  • 1. Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity.
    Guo X; Bourgeois FT; Cai T
    Stat Methods Med Res; 2024 Jul; 33(7):1152-1162. PubMed ID: 38717356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new proportion measure of the treatment effect captured by candidate surrogate endpoints.
    Kobayashi F; Kuroki M
    Stat Med; 2014 Aug; 33(19):3338-53. PubMed ID: 24782344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES).
    Lassere MN; Johnson KR; Schiff M; Rees D
    BMC Med Res Methodol; 2012 Mar; 12():27. PubMed ID: 22409774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proportion of treatment effect mediated by surrogate endpoints.
    Kuroki M; Shingaki R; Qu Y
    Biom J; 2021 Jan; 63(1):105-121. PubMed ID: 33200481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the feasibility of shortening clinical trial duration using surrogate markers.
    Wang X; Cai T; Tian L; Bourgeois F; Parast L
    Stat Med; 2021 Dec; 40(28):6321-6343. PubMed ID: 34474500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the likelihood reduction factor in a path analysis framework to quantify surrogacy in clinical trials.
    Bloore K; Song Y; Cabral H; Massaro J; LaValley M
    Stat Med; 2021 Dec; 40(28):6373-6386. PubMed ID: 34545969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the value of a censored surrogate outcome.
    Parast L; Tian L; Cai T
    Lifetime Data Anal; 2020 Apr; 26(2):245-265. PubMed ID: 30980316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-to-event surrogate endpoint validation using mediation analysis and meta-analytic data.
    Le Coënt Q; Legrand C; Rondeau V
    Biostatistics; 2023 Dec; 25(1):98-116. PubMed ID: 36398615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials.
    Rotolo F; Paoletti X; Michiels S
    Comput Methods Programs Biomed; 2018 Mar; 155():189-198. PubMed ID: 29512498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing for heterogeneity in the utility of a surrogate marker.
    Parast L; Cai T; Tian L
    Biometrics; 2023 Jun; 79(2):799-810. PubMed ID: 34874550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A measure of the proportion of treatment effect explained by a surrogate marker.
    Wang Y; Taylor JM
    Biometrics; 2002 Dec; 58(4):803-12. PubMed ID: 12495134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.
    Buyse M; Molenberghs G; Paoletti X; Oba K; Alonso A; Van der Elst W; Burzykowski T
    Biom J; 2016 Jan; 58(1):104-32. PubMed ID: 25682941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
    Molenberghs G; Buyse M; Geys H; Renard D; Burzykowski T; Alonso A
    Control Clin Trials; 2002 Dec; 23(6):607-25. PubMed ID: 12505240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating Covariates into Measures of Surrogate Paradox Risk.
    Shafie Khorassani F; Taylor JMG; Kaciroti N; Elliott MR
    Stats (Basel); 2023 Mar; 6(1):322-344. PubMed ID: 37885610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
    Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
    BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring Surrogacy in Clinical Research: With an application to studying surrogate markers for HIV Treatment-as-Prevention.
    Zhuang R; Chen YQ
    Stat Biosci; 2020 Dec; 12(3):295-323. PubMed ID: 33737982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses.
    Xie W; Halabi S; Tierney JF; Sydes MR; Collette L; Dignam JJ; Buyse M; Sweeney CJ; Regan MM
    JNCI Cancer Spectr; 2019 Mar; 3(1):pkz002. PubMed ID: 31360890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation.
    Wheaton L; Papanikos A; Thomas A; Bujkiewicz S
    Med Decis Making; 2023 Jul; 43(5):539-552. PubMed ID: 36998240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.